Ultragenyx

#药闻简讯# $Ultragenyx(RARE)$ 2025 年营收指引：总营收预计在 $6.4 亿至 $6.7 亿美元之间，其中 Crysvita 营收为 $4.6 亿至 $4.8 亿美元，Dojolvi 营收为 $9,000 万至 $1 亿美元。
UX143 OI Ⅲ期临床试验数据（来自 Orbit&Cosmic 研究）预计将于年底前公布。

$Ultragenyx(RARE)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-25-103026  Act: 34  Size: 537 KB 网页链接

$Ultragenyx(RARE)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0000950170-25-096912  Act: 33  Size: 566 KB 网页链接

$Ultragenyx(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001677455-25-000005  Size: 4 KB 网页链接

$Ultragenyx(RARE)$ 8-K Current report, item 8.01 Accession Number: 0000950170-25-109570  Act: 34  Size: 154 KB 网页链接

$Ultragenyx(RARE)$ 8-K Current report, item 8.01 Accession Number: 0000950170-25-100918  Act: 34  Size: 154 KB 网页链接

$Ultragenyx(RARE)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-25-103290  Act: 34  Size: 11 MB 网页链接

$Ultragenyx(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-25-113446  Size: 4 KB 网页链接

$Ultragenyx(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-209387  Size: 4 KB 网页链接

$Ultragenyx(RARE)$ 144 Report of proposed sale of securities Accession Number: 0001950047-25-007039  Act: 33  Size: 4 KB 网页链接

$Ultragenyx(RARE)$ 8-K Current report, item 8.01 Accession Number: 0000950170-25-113553  Act: 34  Size: 165 KB 网页链接